Aspect Biosystems from Vancouver secures $165M CAD in Series B to advance 3D-Printed Tissue Therapies
Aspect Biosystems, a Vancouver-based biotech company specializing in 3D-printed tissue implants, has secured $165 million CAD ($115 million USD) in a Series B funding round.